AstraZeneca

February 2, 2017

The Manager – Listing
BSE Limited,
1st Floor, New Trading Ring
Rotunda Buiding, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange plaza, 5th Floor, Plot No.C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s),

Sub: Outcome of the Board Meeting held on Thursday, February 2, 2017

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

At the Board Meeting of the Company held on Thursday, February 2, 2017, the Board of Directors considered and approved the Unaudited Financial Results of the Company for the third quarter ended December 31, 2016. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated February 2, 2017 are enclosed herewith.

Please take the same on record.

Thanking you,

for **AstraZeneca Pharma India Limited**

Pratap Rudra

Pratap Rudra
Company Secretary & Legal Counsel

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor
Manyata Embassy Business Park
Rachenahalli, Outer Ring Road
Bangalore - 560045, INDIA

TEL : +91 80 67748000
FAX : +91 80 67748857
CIN : L24231KA1979PLC003563
WEB : **www.astrazeneca.com/india**

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 67749000
FAX : +91 80 28462208
+91 80 67749628

AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045

Part I

Rs in lakhs (except in respect of Sl No.16)

Statement of unaudited results for the quarter and nine months ended 31 December 2016

Sl No.	Particulars	3 months ended 31/12/2016 (Unaudited)	3 months ended 30/09/2016 (Unaudited)	3 months ended 31/12/2015 (Unaudited)	9 months ended 31/12/2016 (Unaudited)	9 months ended 31/12/2015 (Unaudited)	Previous year ended 31/03/2016 (Audited)
1	**Income from operations**						
	a) Net sales/ income from operations (net of excise duty)	14,112.34	13,614.37	14,456.08	41,535.94	39,294.50	52,645.98
	b) Other operating income	916.26	202.18	2.13	1,263.29	1,196.69	3,727.25
	Total income from operations (net)	**15,028.60**	**13,816.55**	**14,458.21**	**42,799.23**	**40,491.19**	**56,373.23**
2	**Expenses**						
	(a) Cost of materials consumed	244.49	305.72	506.07	870.04	2,607.11	3,475.85
	(b) Purchase of stock-in-trade	3,567.46	2,762.03	4,628.61	11,407.39	11,067.32	15,888.71
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	893.09	1,348.87	272.13	1,319.11	1,062.76	541.52
	(d) Employee benefits expense	3,811.90	4,695.86	3,881.28	12,740.30	11,848.51	16,934.52
	(e) Depreciation and amortisation expense	401.92	406.29	444.46	1,215.10	1,318.93	1,742.64
	(f) Selling, marketing and distribution	1,861.29	1,438.66	1,387.20	4,564.88	4,959.72	7,194.29
	(g) Other expenses	3,156.25	2,943.07	2,618.99	8,483.92	7,624.65	10,696.60
	Total expenses	**13,936.40**	**13,900.50**	**13,738.74**	**40,600.74**	**40,489.00**	**56,474.13**
3	**Profit/ (loss) from operations before other income, finance costs and exceptional items (1-2)**	**1,092.20**	**(83.95)**	**719.47**	**2,198.49**	**2.19**	**(100.90)**
4	Other income (Refer note 3)	983.27	181.65	147.95	1,321.12	467.98	677.27
5	**Profit/ (loss) from ordinary activities before finance costs and exceptional items (3+4)**	**2,075.47**	**97.70**	**867.42**	**3,519.61**	**470.17**	**576.37**
6	Finance costs	-	-	-	-	-	-
7	**Profit/ (loss) from ordinary activities after finance costs but before exceptional items (5-6)**	**2,075.47**	**97.70**	**867.42**	**3,519.61**	**470.17**	**576.37**
8	Exceptional items	-	-	-			-
9	**Profit/ (loss) from ordinary activities before tax (7+8)**	**2,075.47**	**97.70**	**867.42**	**3,519.61**	**470.17**	**576.37**
10	Tax expense	479.18	19.04	-	787.85	-	50.47
11	**Net profit/(loss) from ordinary activities after tax (9-10)**	**1,596.29**	**78.66**	**867.42**	**2,731.76**	**470.17**	**525.90**
12	Extraordinary Item	-	-	-	-	-	-
13	**Net profit/(loss) for the period (11-12)**	**1,596.29**	**78.66**	**867.42**	**2,731.76**	**470.17**	**525.90**
14	**Paid-up equity share capital** (Face value of Rs 2 per equity share)	**500.00**	**500.00**	**500.00**	**500.00**	**500.00**	**500.00**
15	**Reserves excluding revaluation reserves as per the balance sheet of previous accounting year**						**15,101.43**
16	**Basic and diluted earnings per share (of Rs 2 each) [not annualised]**	**6.39**	**0.31**	**3.47**	**10.93**	**1.88**	**2.10**

Notes:

1. The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 2nd February 2017.
2. The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. 'Others' comprises of service income pertaining to clinical trials.
3. Other Income for the quarter and nine months ended December 31, 2016 includes consideration received (translating into a gain for an equivalent amount) from sale of trademarks and related know-how of discontinued products to an unrelated pharma company amounting to Rs. 800 lakhs.
4. AstraZeneca Pharmaceuticals AB, Sweden, the promoter of the Company vide its letter dated 1 March 2014, had proposed voluntary delisting of equity shares from stock exchanges ('Delisting Proposal'). The Board of Directors of the Company at their meeting held on 15 March 2014, had accorded approval for the Delisting Proposal. Further, the Delisting Proposal has been approved by the requisite majority of shareholders of the Company as required under Regulation 8 of SEBI (Delisting of Equity Shares) Regulations, 2009. Securities Exchange Board of India (SEBI) in its Order dated 24 June 2014 has issued directions to Bombay Stock Exchange and National Stock Exchange to closely monitor the entire delisting process of the Company and the Company shall finally purchase shares from the public shareholders in the delisting offer only after seeking approval from Bombay Stock Exchange and National Stock Exchange. The Company has received in-principle approval of National Stock Exchange and Bombay Stock Exchange, for voluntary delisting of equity shares from the said exchanges. A writ petition had been filed by two shareholders of the Company before the Honourable High Court of Judicature at Bombay ("the Court"), seeking inter-alia an order from the Court, restraining the Company and AstraZeneca Pharmaceuticals AB, Sweden ("AZPAB") from implementing the Delisting Proposal. The Court which heard the petition on 8 October 2014 has disposed off the same, with the directions that the Petitioners as well as the Company and AZPAB are at liberty to prefer appeal against SEBI Order dated 24 June 2014, to the Securities Appellate Tribunal (SAT), within six weeks and until the SAT hears and disposes of the Petitioners' appeal, the Company and AZPAB shall not take any further steps in the process of delisting of equity shares of the Company. The SAT was requested to hear and decide the appeals as expeditiously as possible and preferably by 28 February 2015. Further, an appeal has also been filed by two shareholders of the Company before the SAT, Mumbai, against part of SEBI's Order dated 24 June 2014, in relation to Delisting Proposal. The case was posted for hearing on multiple dates during the year ended 31 March 2015. At the hearing held on 5 May 2015, the SAT posted the matter to be heard on 9 July 2015 which was subsequently rescheduled for hearing on 11 August 2015. In the final hearing held on 11 September 2015, the SAT has disposed off the appeal directing SEBI to complete the investigation within a period of six months from date of its order and pass appropriate order on merits. The SAT has further directed the Company and the Promoter not to proceed with the delisting of equity shares till the completion of investigation and passing of the above mentioned order on merits by SEBI. Also the SAT has directed the Company and the Promoters that if the order passed by SEBI on merits is adverse to the appellants, then the said order shall not be given effect to from the date of passing the said order till it is communicated to the appellants and four weeks thereafter.
5. The above statement of financial results has been reviewed by the statutory auditors. The statutory auditors have issued an unqualified review report. The review report will be filed with the stock exchange and will also be available on the company's website.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Price Waterhouse & Co Chartered Accountants LLP
LLPIN AAC-4362
FRN 304026E/E-300009
Bangalore

Sanjay Murdeshwar
Managing Director

Bangalore
Dated: 2 February 2017

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Segment wise revenue, results and capital employed

(Rs in lakhs)

Sl.no.	Particulars	3 months ended 31/12/2016 (Unaudited)	3 months ended 30/09/2016 (Unaudited)	3 months ended 31/12/2015 (Unaudited)	9 months ended 31/12/2016 (Unaudited)	9 months ended 31/12/2015 (Unaudited)	Previous year ended 31/03/2016 (Audited)
1	**Segment revenue**						
	(a) Healthcare	14,276.48	13,207.52	14,319.59	41,078.34	39,964.67	55,402.82
	(b) Others	752.12	609.03	138.62	1,720.89	526.52	970.41
	Net sales/income from operations	**15,028.60**	**13,816.55**	**14,458.21**	**42,799.23**	**40,491.19**	**56,373.23**
2	**Segment results**						
	Profit/(Loss) before tax and interest						
	(a) Healthcare	1,080.71	(93.99)	709.80	2,165.87	(21.89)	(135.16)
	(b) Others	11.49	10.04	9.67	32.62	24.08	34.26
	Total	**1,092.20**	**(83.95)**	**719.47**	**2,198.49**	**2.19**	**(100.90)**
	Add: Other income	983.27	181.65	147.95	1,321.12	467.98	677.27
	Total Profit/(Loss) before tax	**2,075.47**	**97.70**	**867.42**	**3,519.61**	**470.17**	**576.37**
3	**Capital employed**						
	(a) Healthcare	6,120.00	6,381.17	5,110.87	6,120.00	5,110.87	6,791.87
	(b) Others	(1,157.48)	(358.10)	(419.26)	(1,157.48)	(419.26)	(165.94)
	(c) Unallocated	13,370.69	10,713.82	10,854.09	13,370.69	10,854.09	8,975.50
	Total	**18,333.21**	**16,736.89**	**15,545.70**	**18,333.21**	**15,545.70**	**15,601.43**

Notes :

1 Certain assets and liabilities not identifiable with individual business segments are used interchangeably between the business segments. Hence, such assets and liabilities have not been allocated to any segment.

Price Waterhouse & Co Chartered Accountants LLP
LLPIN AAC-4362
FRN 304026E/E-300009
Bangalore